Clinical-stage Australian biotechnology company Immutep (ASX:IMM) has completed enrolment in the investigator-initiated EFTISARC-NEO trial.
Immutep completes patient enrolment for EFTISARC-NEO Phase 2 trial
January 22, 2025 Australian Biotech
Latest Video
New Stories
-
Health spending under increasing pressure, as department looks to offsets
July 9, 2025 - - Latest News -
AusBiotech welcomes 27 new members in first half of 2025
July 9, 2025 - - Latest News -
Consortium established to co-design new telehealth standards
July 8, 2025 - - Latest News -
South Australia expands flu vax availability in response to record outbreak
July 8, 2025 - - Latest News -
MedAdvisor restates focus on US following completion of ANZ business sale
July 8, 2025 - - Latest News -
More companies are exercising their rights, and they are perfectly entitled
July 7, 2025 - - Latest News -
Neurotech’s Rett Syndrome trial results published in scientific journal
July 7, 2025 - - Australian Biotech